Thomas A. Miller

Optimization of biaryl Selective HDAC1&2 Inhibitors (SHI-1:2)

David J. Witter, Paul E. Harrington, Kevin J. Wilson et al. · Bioorganic & Medicinal Chemistry Letters · 2007 · 95 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +12

De novo and recessive forms of congenital heart disease have distinct genetic and phenotypic landscapes

W. Scott Watkins, Edgar J. Hernández, Sergiusz Wesołowski et al. · Nature Communications · 2019 · 90 citations · Full text

Life Sciences, Genetics, Molecular Genetics +17

Histone Deacetylase Inhibitors: Development as Cancer Therapy

Paul A. Marks, Victoria M. Richon, Wm. Kevin Kelly et al. · Novartis Foundation symposium · 2004 · 85 citations

Medicine, Oncology, Pharmacology +14

Creating the Exceptional Patient Experience in One Academic Health System

Vivian S. Lee, Thomas A. Miller, Chrissy Daniels et al. · Academic Medicine · 2015 · 56 citations · Full text

Public Affairs, Health Services Administration, Health Systems +17

Molecular and Biologic Analysis of Histone Deacetylase Inhibitors with Diverse Specificities

Andrea Newbold, Geoffrey M. Matthews, Michael Bots et al. · Molecular Cancer Therapeutics · 2013 · 46 citations

Medicine, Oncology, Pharmacology +17